BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26124352)

  • 1. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
    Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
    Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib-induced hyperammonemic encephalopathy.
    Kuo JC; Parakh S; Yip D
    J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer.
    Raissouni S; Quraishi Z; Al-Ghamdi M; Monzon J; Tang P; Vickers MM
    BMC Res Notes; 2015 Oct; 8():538. PubMed ID: 26438070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose regorafenib-induced hypertensive crisis.
    Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
    Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
    Mihara Y; Yamaguchi K; Nakama T; Nakayama G; Kamei H; Ishibashi N; Uchida S; Akagi Y; Ogata Y
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):233-6. PubMed ID: 25743146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
    Mitchell J; Khoukaz T; McNeal D; Brent L
    Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
    Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
    Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to
    Van Weehaeghe D; Gheysens O; Vandecaveye V; Schöffski P; Van Laere K; Deroose CM
    BMC Cancer; 2018 Mar; 18(1):253. PubMed ID: 29506493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
    Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
    Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral sensorineural hearing loss induced by regorafenib.
    Cheng J; Wang L; Zhu LN; Wang L
    J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
    Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
    Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.